CRO Clinlogix has expanded its reach in Europe with the acquisition of German CRO ikfe CRO GmbH.
The acquisition will boost Clinlogix’s European operations, also based in Germany, which offers full service development of drugs, devices and diagnostics and has special expertise in diabetes, cardiovascular disease and oncology.
JeanMarie Markham, CEO of Clinlogix, said, “ikfe CRO is a high quality acquisition that provides us with the personnel, relationships and infrastructure to bring our unique service mix to clients on a worldwide basis.”
“This acquisition greatly strengthens our strategic resources, knowledge base and infrastructure in the largest pharmaceutical market in the world,” Dr. Marco Grenningloh, PhD, COO and managing director of Clinlogix Europe, added. “ikfe CRO was a highly respected regional service provider, and their specialized expertise and in-depth understanding are further enhancing our ability to provide knowledgeable, high quality services to our clients around the globe.”
The company in July also expanded into Latin America with a new office in Medellin, Colombia. That office aims to be a part of a hub assisting academic inventors, allowing public and private companies to validate their early and later stage technologies.